

Data Item	NAACCR Item Number	Collection Dates
NAACCR Record Version	50	2003 - present
Tumor Record Number	60	2026
Address at Dx City	70	1995 - present
Address at Dx State	80	1995 - present
FIPS County Code at DX	90	1995 - present
Address at Dx Zip Code	100	1995 - present
Address at Dx-Country	102	2013 - present
Marital Status at Dx	150	2022 - present
Race 1	160	1995 - present
Race 2	161	2001 - present
Race 3	162	2001 - present
Race 4	163	2001 - present
Race 5	164	2001 - present
Spanish/Hispanic Origin	190	1995 - present
Sex Assigned at Birth	225	2026
Age at Diagnosis	230	1995 - present
Date of Birth	240	1995 - present
Birthplace-State	252	2013 - present
Birthplace-Country	254	2013 -present
Text Usual Occupation	310	2010 - present
Text Usual Industry	320	2010 - present
Tobacco Use Smoking Status	344	2022 - present
Sequence Number Central	380	1995 - present
Date of Initial Diagnosis	390	1995 - present
Primary Site	400	1995 - present
Laterality	410	1995 - present
Diagnostic Confirmation	490	1995 - present
Type of Reporting Source	500	1995 - present
Histologic Type ICD-O-3 2001 and forward	522	2001 - present
Behavior 2001 and forward	523	2001 - present
Reporting Facility	540	1995 - present
NPI Reporting Facility (Derived)	545	2009 - present
Registry/Accession Number	550	1995 - present
Sequence Number Hospital	560	1995 - present
Abstractor Initials	570	1995 - present
Date of Admission/First Contact	580	1995 - present
Class of Case	610	1998 - present
Primary Payer at DX	630	2007 - present

RX Hosp—Surg Prim Site 2023	671	2023 - present
RX Hosp—Scope of Reg LN Sur	672	2022 - present
RX Hosp—Surg Oth Reg/Dis	674	2022 - present
Date Regional Lymph Node Dissection	682	2022 – present
RX Hosp--Chemo	700	2022 - present
RX Hosp--Hormone	710	2022 - present
RX Hosp—BRM (Immunotherapy)	720	2022 - present
RX Hosp--Other	730	2022 - present
RX Hosp--Rcon Breast	751	2024 - present
Tumor Size Summary	756	2016 - present
Summary Stage 2018	764	2018 - present
EOD Primary Tumor	772	2022 - present
EOD Regional Nodes	774	2022 - present
EOD Metastases	776	2022 - present
Regional Nodes Positive	820	1998 - present
Regional Nodes Examined	830	1998 - present
Date of Sentinal Lymph Node Biopsy	832	2022 - present
Sentinel Lymph Nodes Examined	834	2022 - present
Sentinel Lymph Nodes Positive	835	2022 - present
AJCC ID	995	2018 - present
AJCC TNM Clin T	1001	2018 - present
AJCC TNM Clin N	1002	2018 - present
AJCC TNM Clin M	1003	2018 - present
AJCC TNM Clin Stage Group	1004	2018 - present
AJCC TNM Path T	1011	2018 - present
AJCC TNM Path N	1012	2018 - present
AJCC TNM Path M	1013	2018 - present
AJCC TNM Path Stage Group	1014	2018 - present
AJCC TNM Post Therapy Path (yc) T	1021	2021 - present
AJCC TNM Post Therapy Path (yc) N	1022	2021 - present
AJCC TNM Post Therapy Path (yc) M	1023	2021 - present
AJCC TNM Post Therapy Path Stage Group	1024	2021 - present
AJCC TNM Clin T Suffix	1031	2021 - present
AJCC TNM Path T Suffix	1032	2021- present
AJCC TNM Post Therapy Path (yc) T Suffix	1033	2021 - present
AJCC TNM Clin N Suffix	1034	2021 - present
AJCC TNM Path N Suffix	1035	2021- present
AJCC TNM Post Therapy Path (yc) N Suffix	1036	2021 –present

TNM Edition Number	1060	2015 - present
AJCC TNM Post Therapy Clin (yc) T	1062	2021- present
AJCC TNM Post Therapy Clin (yc) T Suffix	1063	2021- present
AJCC TNM Post Therapy Clin (yc) N	1064	2021- present
AJCC TNM Post Therapy Clin (yc) N Suffix	1065	2021- present
AJCC TNM Post Therapy Clin (yc) M	1066	2021- present
Grade Post Therapy Clinical (yc)	1068	2021- present
Mets at Diagnosis-Bone	1112	2022 - present
Mets at Diagnosis-Brain	1113	2022 - present
Mets at Diagnosis – Distant LNs	1114	2022 - present
Mets at Diagnosis – Liver	1115	2022 - present
Mets at Diagnosis-Lung	1116	2022 - present
Mets at Diagnosis-Other	1117	2022 - present
Pediatric ID	1132	2025 - present
Pediatric ID Version Current	1133	2025 - present
Pediatric ID Version Original	1134	2025 - present
Toronto Version Number	1135	2025 - present
Pediatric Primary Tumor	1136	2025 - present
Pediatric Regional Nodes	1137	2025 - present
Pediatric Mets	1138	2025 - present
Derived Pediatric T	1142	2025 - present
Derived Pediatric N	1143	2025 - present
Derived Pediatric Stage Group	1145	2025 - present
Toronto T	1146	2025 - present
Toronto N	1147	2025 - present
Derived Pediatric M	1144	2025 - present
Toronto M	1148	2025 - present
Toronto Stage Group	1149	2025 - present
Post Transplant Lymphoproliferative Disorder-PTLD	1172	2025 - present
PD-L1	1174	2025 - present
Spread Through Air Spaces (STAS)	1176	2026
Residual Cancer Burden (RCB)	1178	2026
Residual Cancer Burden Class	1179	2026
Lymphovascular Invasion (testis and penis only)	1182	2011 - present
White Blood Cell Count	1184	2025 - present
Intl Neuroblastoma Risk Grp Stage Sys (INRGSS)	1185	2025 - present

n-MYC Amplification	1186	2025 - present
Intl Neuroblastoma Path Prog Class (INPC)	1187	2025 - present
IRSS Stage for Eye-2	1188	2025 - present
Chromosome 16q: Loss of Heterozygosity	1189	2025 - present
Chromosome 1q Status	1190	2025 - present
EWSR1-FLI1 fusion	1191	2025 - present
Pretext Clinical Staging	1192	2025 - present
FOXO1 Gene Rearrangements	1193	2025 - present
RX Date Surgery	1200	1995 - present
Rx Date Radiation	1210	1995 - present
Date Chemotherapy Started	1220	2010 - present
Date Hormone Therapy Started	1230	2010 - present
Date Immunotherapy (BRM) Started	1240	2010 - present
Date Other Treatment Started	1250	1995 - present
Date of Initial Treatment	1260	2010 - present
RX - Summary Treatment Status	1285	2010 - present
RX Summ—Surg Prim Site 2023	1291	2023 - present
RX Summary - Scope of Reg LN Surgery	1292	2001 - present
RX Summary - Surgery Other/Dist RX Code	1294	1998 - present
Surgical Margins of Primary Site	1320	2022 - present
RX Summ—Recon Breast	1335	2024 - present
Reason for No Surgery	1340	1998 - 2002 - present 2026
RX Summary - Surgery/Radiation Sequence	1380	2004 - present
Chemotherapy Code	1390	1995 - present
Hormone Code	1400	1995 - present
Immunotherapy (BRM) Code	1410	1995 - present
Other Treatment Code	1420	1995 - present
Reason for no Radiation	1430	1998 - present
Phase I Dose per Fraction	1501	2022 - present
Phase I Radiation External Beam Planning Tech	1502	2022 - present
Phase I Number of Fractions	1503	2022 - present
Phase I Radiation Primary Treatment Volume	1504	2022 - present

Phase I Radiation to Draining Lymph Nodes	1505	2022 - present
Phase I Radiation Treatment Modality	1506	2018 - present
Phase I Total Dose	1507	2022 - present
Phase II Dose per Fraction	1511	2022 - present
Phase II Radiation External Beam Planning Tech	1512	2022 - present
Phase II Number of Fractions	1513	2022 - present
Phase II Radiation Primary Treatment Volume	1514	2022 - present
Phase II Radiation to Draining Lymph Nodes	1515	2022 - present
Phase II Radiation Treatment Modality	1516	2022 - present
Phase II Total Dose	1517	2022 - present
Phase III Dose per Fraction	1521	2022 - present
Phase III Radiation External Beam Planning Tech	1522	2022 - present
Phase III Number of Fractions	1523	2022 - present
Phase III Radiation Primary Treatment Volume	1524	2022 - present
Phase III Radiation to Draining Lymph Nodes	1525	2022 - present
Phase III Radiation Treatment Modality	1526	2022 - present
Phase III Total Dose	1527	2022 - present
Radiation Treatment Discontinued Early	1531	2022 - present
Number of Phases of Rad Treatment to this Volume	1532	2022 - present
Total Dose	1533	2022 - present
Neoadjuvant Therapy	1632	2022 - present
Neoadjuvant Therapy-Clinical Response	1633	2022 - present
Neoadjuvant Therapy-Treatment Effect	1634	2022 - present
RX Summary - Systemic/Surgery Sequence	1639	2006 - present
Date of Last Followup or Death (Contact)	1750	1995 - present
Vital Status	1760	1998 - present
Cancer Status	1770	2022 - present

Date of Last Cancer (Tumor) Status	1772	2022 - present
Follow Up Source (Derived)	1790	2009 - present
Follow Up Source	1791	1995 - present
Current Address City	1810	2022 - present
Current Address - State	1820	2022 - present
Current Address - Zip Code	1830	2022 - present
Current Address - Country	1832	2022 - present
Recurrence Date--1st	1860	2022 - present
Recurrence Type--1st	1880	2022 - present
Underlying Cause of Death	1910	2022 - present
Place of Death-State	1942	2013 - present
Place of Death-Country	1944	2013 - present
Date Abstracted	2090	1995 - present
CoC Accredited Flag	2152	2018 - present
Last Name	2230	1995 - present
Birth Surname	2232	2021 - present
First Name	2240	1995 - present
Middle Name	2250	1995 - present
Name--Suffix	2270	2022 - present
Patient Name Alias	2280	1995 - 2002 2006 - present
Medical Record Number	2300	1995 - present
Medicare Beneficiary Identifier	2315	2021 - present
Social Security Number	2320	1995 - present
Address at Dx Street Address	2330	1995 - present
Address at Dx Supplemental	2335	2006 - present
Current Address Number and Street	2350	2022 - present
Current Address Supplemental	2355	2022 - present
Telephone	2360	2022 - present
Physician Follow Up	2470	2006 - present
Summary Stage Documentation	2520-2570, 2600	1995 - present
Final DX Primary Site and Laterality	2580	1995 - present
Final DX Hist/Beh/Grade	2590	1995 - present
RX Text Surgery	2610	2004 - present
RX Text - Radiation	2620, 2630	2004 - present
RX Text - Chemotherapy	2640	2004 - present
RX Text - Hormone	2650	2004 - present
RX Text - Immunotherapy (BRM)	2660	2004 - present
RX Text - Other	2670	2004 - present
Other Pertinent Information	2680	1995 - present
RX Date Mst Defn Srg	3170	2015 - present

RX Date - Systemic	3230	2004 - 2010 - present	2022
RX Summary Transplant/Endocrine	3250	2003 - present	
SEER Site Specific Factor 1	3700	2022 - present	
Secondary Diagnosis 1	3780	2023 - present	
Secondary Diagnosis 2	3782	2023 - present	
Secondary Diagnosis 3	3784	2023 - present	
Secondary Diagnosis 4	3786	2023 - present	
Secondary Diagnosis 5	3788	2023 - present	
Secondary Diagnosis 6	3790	2023 - present	
Secondary Diagnosis 7	3792	2023 - present	
Secondary Diagnosis 8	3794	2023 - present	
Secondary Diagnosis 9	3796	2023 - present	
Secondary Diagnosis 10	3798	2023 - present	
Schema ID	3800	2018 - present	
Chromosome 1p: Loss of Heterozygosity (LOH)	3801	2022 - present	
Chromosome 19q: Loss of Heterozygosity (LOH)	3802	2022 - present	
Adenoid Cystic Basaloid Pattern	3803	2022 - present	
Adenopathy	3804	2022 - present	
AFP Post-Orchiectomy Lab Value	3805	2022 - present	
AFP Post-Orchiectomy Range	3806	2022 - present	
AFP Pre-Orchiectomy Lab Value	3807	2022 - present	
AFP Pre-Orchiectomy Range	3808	2022 - present	
AFP Pretreatment Interpretation	3809	2022 - present	
AFP Pretreatment Lab Value	3810	2022 - present	
Anemia	3811	2022 - present	
B symptoms	3812	2022 - present	
Bilirubin Pretreatment Total Lab Value	3813	2022 - present	
Bilirubin Pretreatment Unit of Measure	3814	2022 - present	
Bone Invasion	3815	2022 - present	
Brain Molecular Markers	3816	2018 – present	
Breslow Tumor Thickness	3817	2018 – present	
CA-125 Pretreatment Interpretation	3818	2022 - present	
CEA Pretreatment Interpretation	3819	2022 - present	
CEA Pretreatment Lab Value	3820	2022 - present	
Circumferential Resection Margin (CRM)	3823	2022 - present	
Creatinine Pretreatment Lab Value	3824	2022 - present	

Creatinine Pretreatment Unit of Measure	3825	2022 - present
Estrogen Receptor Percent Positive or Range	3826	2022 - present
Estrogen Receptor Summary	3827	2018 – present
Esophagus and EGJ Tumor Epicenter	3829	2022 - present
Extranodal Extension Clin (non-Head and Neck)	3830	2022 - present
Extranodal Extension Head and Neck Clinical	3831	2022 - present
Extranodal Extension Head and Neck Pathological	3832	2022 - present
Extranodal Extension Path (non-Head and Neck)	3833	2022 - present
FIGO Stage	3836	2022 - present
Gestational Trophoblastic Prognostic Scoring Index	3837	2022 - present
Gleason Patterns Clinical	3838	2021 - present
Gleason Patterns Pathological	3839	2021 - present
Gleason Score Clinical	3840	2021 - present
Gleason Score Pathological	3841	2021 - present
Gleason Tertiary Pattern	3842	2021 - present
Grade Clinical	3843	2018 – present
Grade Pathological	3844	2018 - present
Grade Post Therapy Path (yp)	3845	2021 - present
hCG Post-Orchiectomy Lab Value	3846	2022 - present
hCG Post-Orchiectomy Range	3847	2022 - present
hCG Pre-Orchiectomy Lab Value	3848	2022 - present
hCG Pre-Orchiectomy Range	3849	2022 - present
HER2 Overall Summary	3855	2018 – present
Heritable Trait	3856	2022 - present
High Risk Cytogenetics	3857	2022 - present
High Risk Histologic Features	3858	2022 - present
International Normalized Ratio Prothrombin Time	3860	2022 - present
Ipsilateral Adrenal Gland Involvement	3861	2022 - present
JAK2	3862	2022 - present
Ki-67	3863	2022 - present
Invasion Beyond Capsule	3864	2022 - present

KIT Gene Immunohistochemistry	3865	2022 - present
KRAS	3866	2022 - present
LDH Post-Orchiectomy Range	3867	2022 - present
LDH Pre-Orchiectomy Range	3868	2022 - present
LDH Level	3869	2022 - present
LDH Upper Limits of Normal	3870	2022 - present
LN Assessment Method Femoral-Inguinal	3871	2022 - present
LN Assessment Method Para-Aortic	3872	2022 - present
LN Assessment Method Pelvic	3873	2022 - present
LN Distant Assessment Method	3874	2022 - present
LN Distant: Mediastinal, Scalene	3875	2022 - present
LN Head and Neck Levels I-III	3876	2022 - present
LN Head and Neck Levels IV-V	3877	2022 - present
LN Head and Neck Levels VI-VII	3878	2022 - present
LN Head and Neck Other	3879	2022 - present
LN Isolated Tumor Cells (ITC)	3880	2022 - present
LN Positive Axillary Level I-II	3882	2022 - present
LN Size	3883	2022 - present
Lymphocytosis	3885	2022 - present
Major Vein Involvement	3886	2022 - present
Measured Basal Diameter	3887	2022 - present
Measured Thickness	3888	2022 - present
Methylation of O6-Methylguanine-Methyltransferase	3889	2022 - present
Microsatellite Instability (MSI)	3890	2018 - present
Mitotic Count Uveal Melanoma	3892	2022 - present
Mitotic Rate Melanoma	3893	2022 - present
NCCN International Prognostic Index (IPI)	3896	2022 - present
Number of Cores Examined	3897	2022 - present
Number of Cores Positive	3898	2022 - present
Number of Examined Para-Aortic Node	3899	2022 - present
Number of Examined Pelvic Nodes	3900	2022 - present
Number of Positive Para-Aortic Nodes	3901	2022 - present
Number of Positive Pelvic Nodes	3902	2022 - present
Oncotype Dx Recurrence Score-Invasive	3904	2022 - present
Organomegaly	3907	2022 - present
Perineural Invasion	3909	2022 - present

Peripheral Blood Involvement	3910	2022 - present
Peritoneal Cytology	3911	2022 - present
Pleural Effusion	3913	2022 - present
Progesterone Receptor Percent Positive or Range	3914	2022 - present
Progesterone Receptor Summary	3915	2018 - present
Profound Immune Suppression	3918	2022 - present
EOD Prostate Pathologic Extension	3919	2022 - present
PSA (Prostatic Specific Antigen) Lab Value	3920	2018 – present
Residual Tumor Volume Post Cytoreduction	3921	2022 - present
Response to Neoadjuvant Therapy	3922	2022 - present
S Category Clinical	3923	2022 - present
S Category Pathological	3924	2022 - present
Sarcomatoid Features	3925	2022 - present
Schema Discriminator 1	3926	2018 - present
Schema Discriminator 2	3927	2018 - present
Schema Discriminator 3	3928	2022 - present
Separate Tumor Nodules	3929	2022 - present
Serum Albumin Pretreatment Level	3930	2022 - present
Serum Beta-2 Microglobulin Pretreatment Level	3931	2022 - present
LDH Lab Value	3932	2018 – present
Thrombocytopenia	3933	2022 - present
Tumor Deposits	3934	2022 - present
Ulceration	3936	2022 - present
Visceral and Parietal Pleural Invasion	3937	2022 - present
ALK Rearrangement	3938	2022 - present
EGFR Mutational Analysis	3939	2022 - present
BRAF Mutational Analysis	3940	2022 - present
NRAS Mutational Analysis	3941	2022 - present
CA 19-9 PreTX Lab Value	3942	2022 - present
Macroscopic Evaluation of the Mesorectum	3950	2022 - present
p16	3956	2022 - present
LN Status Pelvic	3957	2022 - present
LN Status Para-Aortic	3958	2022 - present
LN Status Femoral-Inguinal	3959	2022 - present
Histologic Subtype	3960	2023- present
Clinical Margin Width	3961	2023 - present

Brain Primary Tumor Location	
------------------------------	--

3964	2024 - present
------	----------------

[illegible]

[illegible]

CoC

CoC

CoC

CoC

CoC

Derived

Derived

Derived

Derived

Derived

Derived

Derived

Derived

Derived

Derived

Derived

Derived

CoC

CoC

CoC

[illegible]

CoC

CoC

Derived

Derived

Linkage

CoC

Derived

CoC

CoC

CoC

CoC

CoC

CoC

CoC

CoC

CoC

CoC

CoC

CoC

CoC

CoC

CoC

CoC

CoC

CoC

CoC

CoC

CoC

CoC

CoC

CoC

CoC

CoC

CoC

CoC

CoC

CoC

CoC

CoC

CoC

CoC

CoC

CoC

CoC

CoC

CoC

CoC

CoC

CoC

CoC

CoC

CoC

CoC

CoC

CoC

CoC

--

CoC

CoC

CoC

CoC

CoC

CoC

CoC

CoC

CoC

CoC

CoC

CoC

